Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sanofi Ord Shs SNYNF

Healthcare
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood... see more

Recent & Breaking News (OTCPK:SNYNF)

Media Advisory / Photo Session and Interview Opportunity - Exclusive meeting with Alexandre Bilodeau, international athlete and new brand ambassador of Synvisc-One® by Sanofi Canada

Canada NewsWire January 13, 2014

Regeneron Announces Amendment to Investor Agreement with Sanofi

PR Newswire January 13, 2014

Genzyme and Alnylam Expand Collaboration on Rare Genetic Diseases

Business Wire January 13, 2014

RDInvesting Provides Investors with Free In-Depth Equity Reports on MDRX, SNY, SRPT and TLOG

Accesswire January 7, 2014

Genzyme Receives Complete Response Letter from FDA on Lemtrada(TM) (alemtuzumab) Application

Business Wire December 30, 2013

Genzyme's Lemtrada(TM) Approved in Australia for Treatment of Multiple Sclerosis

Business Wire December 19, 2013

Sanofi and Regeneron Announce Collaboration with American College of Cardiology for PCSK9 Inhibitor Clinical Program

PR Newswire December 19, 2013

Genzyme and NORD Establish Program to Help Undiagnosed Patients with Rare Diseases

Business Wire December 16, 2013

FDA Grants Priority Review for Genzyme's Cerdelga(TM) (eliglustat), an Investigational Oral Therapy for Gaucher Disease

Business Wire December 11, 2013

Sanofi US Launches Second Innovation Challenge: Collaborate | Innovate

PR Newswire December 9, 2013

New Data Support Flexibility in Timing of Administration for Sanofi's Lyxumia(R)

PR Newswire December 5, 2013

New Data Support Flexibility in Timing of Administration for Sanofi's Lyxumia®

Canada NewsWire December 5, 2013

The Multiple Sclerosis Association of America Announces Swim for MS - Why I Swim Campaign

PR Newswire December 4, 2013

Sanofi Announces New Phase 3 Results for Investigational New Insulin U300

PR Newswire December 3, 2013

Hagens Berman: Statement of Steve W. Berman, lead attorney in US-Based Thalidomide Cases, in Response to Recent $81 million settlement for Australian victims

Business Wire December 2, 2013

Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial

PR Newswire November 22, 2013

Genzyme Convenes 5th Annual Gaucher Leadership Forum in Madrid

Business Wire November 21, 2013

Immune Design Raises Up to $49 Million Series C Financing

PR Newswire October 30, 2013

Sanofi Q3 2013 Marks the End of the Patent Cliff Period

PR Newswire October 30, 2013

Sanofi Q3 2013 - Interview with CFO Jérôme Contamine

Business Wire October 30, 2013